Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The US FDA has recently handed out generic approvals to three companies for both livestock and pet products.
Ashish Life Science has raised INR450 million ($6.3 million) in a series A funding found, which will allow it to expand its Europe, Australia and South Africa.
French firm Ceva Santé Animale is launching MilbeGuard (milbemycin oxime) flavored tablets in the US.
Pharmgate Animal Health has introduced Deracin (chlortetracycline) to control two of the most costly and challenging diseases in the US cattle industry.
European authorities have given the green light for the approval of Virbac's Kriptazen (halofuginone).
Lebanese Veterinary Laboratories (LVL) wants to replicate its strength in the Middle Eastern market in North Africa and Asia.
Barcelona-based Laboratorios Maymo is anticipating a greater amount of export sales by 2020, as it harnesses more distribution deals in new geographies.
Ukrainian company is aiming to take its portfolio of veterinary generics for food animals to a broader European sales base.
Taiwan-based firm Vetnostrum is aiming to diversify its portfolio of veterinary generics in the near future, by moving further into the companion animal sector.
Dutch veterinary generics firm Dopharma is to make a significant addition to its manufacturing capabilities by purchasing assets from Boehringer Ingelheim.
Irish veterinary generics specialist Chanelle has opened a new €10 million ($11.6 million) manufacturing facility at its headquarters in Loughrea, Galway.
Piedmont Animal Health and Norbrook Laboratories are among several firms to have gained recent product approvals from the US FDA.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.